导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.84% | 3134/4773 |
| 近一周 | -2.27% | 3663/5465 |
| 近一月 | -3.51% | 2582/5421 |
| 近一季 | 0.63% | 874/5231 |
| 近半年 | -2.59% | 2204/4920 |
| 近一年 | -0.03% | 2776/4394 |
| 近两年 | 30.06% | 2271/2954 |
| 近三年 | 16.77% | 1592/2253 |
| 成立以来 | 45.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.37% 3608/4961 |
-0.49% 3299/5312 |
- - |
- - |
| 2025 | 11.42% 2747/4813 |
-1.97% 2825/3635 |
1.75% 2177/4076 |
9.02% 3380/4524 |
2.46% 941/4813 |
| 2024 | 17.45% 687/3463 |
3.88% 500/2808 |
0.59% 574/3014 |
15.31% 1754/3129 |
-2.52% 2117/3463 |
| 2023 | -6.68% 868/2656 |
5.43% 784/2280 |
-2.60% 615/2385 |
-1.48% 528/2515 |
-7.76% 2203/2655 |
| 2022 | -14.34% 365/2207 |
-12.61% 640/1919 |
6.49% 687/2016 |
-11.47% 534/2113 |
3.97% 613/2208 |
| 2021 | -6.74% 1019/1822 |
-0.33% 355/1255 |
-2.35% 1202/1330 |
-6.74% 986/1466 |
2.75% 527/1822 |
| 2020 | 28.19% 566/1250 |
-10.40% 775/1028 |
14.08% 571/1067 |
12.78% 364/1164 |
11.19% 557/1184 |
| 2019 | - - |
- - |
- - |
1.34% 412/850 |
7.72% 405/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 兴全沪深300指数(LOF)C VS. 长安沪深300非周期A(740101) |